SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 100.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 100.00%, a 15.68% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 118.60%, a 31.19% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 90.40%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 81.90%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 82.70%, a 12.11% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 94.10%, a 1.40% increase from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 92.80%, a 12.54% decline from fiscal 2020.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 106.10%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 100.00% 10-Q · filed 2026-08-06 | |||||
| 2025-06-30 | 118.60% 10-Q · filed 2026-08-06 | 118.60% 10-Q · filed 2026-08-06 | ||||
| 2024-06-30 | 90.40% 10-Q · filed 2025-08-07 | |||||
| 2023-12-31 | 82.70% 10-K · filed 2024-03-29 | |||||
| 2023-03-31 | 81.90% 10-Q · filed 2024-05-20 | |||||
| 2022-12-31 | 94.10% 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | 97.40% 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | 80.20% 10-Q · filed 2023-08-21 | 85.40% 10-Q · filed 2022-08-10 | ||||
| 2021-12-31 | 92.80% 10-K/A · filed 2023-04-28 | |||||
| 2021-09-30 | 18.70% 10-Q · filed 2021-11-22 | |||||
| 2021-06-30 | 19.80% 10-Q · filed 2021-08-09 | |||||
| 2021-03-31 | 14.30% 10-Q · filed 2021-05-21 | |||||
| 2021-01-14 | 24.20% 10-Q · filed 2021-11-22 | |||||
| 2020-12-31 | 106.10% 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |